Valocordin solution drops for oral administration 20ml №1

Name:
Valocordin solution, drops d / pr. inside in vial. 20ml No. 1
Description:
Transparent, colorless solution, fragrant smell, bitter taste. The main active substance Phenobarbital, Ethylbromizovalerianate Release formDrops Dosage20ml Pharmacological actionCombined drug containing phenobarbital and ethylbromizovalerian. The drug has a sedative or hypnotic effect depending on the dose. Indications for use As part of complex therapy as a symptomatic remedy for functional disorders of the nervous system (neurasthenia and sleep disorders). The drug is intended for short-term use due to the risk of addiction and dependence. Dosage and administration Inside, before meals, with a small amount of liquid. The dose is set individually. Adults are usually prescribed 15-20 drops 3 times a day. In case of disturbed falling asleep, the dose can be increased to 30 drops. The duration of the drug is set individually by the doctor. Use during pregnancy and lactation The drug Valocordin® is contraindicated in pregnant women who are breastfeeding. Precautions The drug contains 56% (v / v) ethyl alcohol, the content of ethyl alcohol in the maximum single dose (30 drops) is 663 mg. The drug should not be taken by patients with alcoholism, pregnant and breastfeeding women, children under 18 years of age, high-risk patients such as patients with liver disease and epilepsy. The simultaneous use of alcoholic beverages with Valocordin® should be avoided. Simultaneous alcohol intake increases the toxicity of phenobarbital. It should be avoided prescribing the drug to patients with depressive disorders, suicidal tendencies, people with drug addiction. Elderly and debilitated patients may respond to phenobarbital by developing marked agitation, depression, and confusion. With prolonged use, accumulation of bromine in the body and the development of intoxication are possible. Phenobarbital can cause the development of addiction, mental and physical dependence. When addiction (tolerance) to phenobarbital develops, the dose required to maintain the same level of effect increases. Abrupt discontinuation of phenobarbital after long-term use in a dependent individual may lead to withdrawal symptoms. In case of signs of intoxication, addiction (tolerance) or dependence, the patient should immediately consult a doctor. Signs of chronic intoxication include confusion, decreased criticism, irritability, insomnia, and somatic complaints. Caution should be exercised when prescribing phenobarbital to patients with acute or chronic pain because paradoxical arousal may develop and important clinical symptoms may be masked. There have been reports of the development of life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) with the use of drugs containing phenobarbital. Very often, a life-threatening skin rash is accompanied by flu-like symptoms. If symptoms of skin reactions appear, the drug should be stopped immediately and consult a doctor. In such cases, the patient should never resume taking Valocordin® again. Interaction with other drugs It is not recommended to take drugs that depress the central nervous system and alcohol at the same time. Medicines containing valproic acid increase the effect of barbiturates. Phenobarbital induces liver enzymes and therefore may accelerate the metabolism of certain drugs that are metabolized by these enzymes (for example, coumarin derivatives, antibacterials and sulfonamides). When taken simultaneously with coumarin derivatives, lamotrigine, thyroid hormones, doxycycline, chloramphenicol, antifungal drugs (azole type), griseofulvin, glucocorticoids or oral contraceptives with Valocordin®, adverse reactions and interactions may occur due to the phenobarbital contained in the preparation. Women taking phenobarbital should be offered non-hormonal methods of contraception. The toxicity of pharmaceutical preparations containing methotrexate is increasing. The effect of phenobarbital on the metabolism of phenytoin is unpredictable, the concentrations of phenytoin and phenobarbital in the blood should be monitored if these drugs are prescribed simultaneously. Sodium valproate and valproic acid inhibit the metabolism of phenobarbital. Interactions associated with the presence of ethyl alcohol in the composition: it is necessary to avoid co-administration of drugs that cause a disulfiram-like reaction (feeling of heat, redness of the skin, vomiting, tachycardia) when taken together with alcohol (disulfiram, cefamandol, cefoperazone, latamoxef, chloramphenicol, chlorpropamide, glibenclamide, glipizide, tolbutamide, griseofulvin, nitro-5-imidazole derivatives (metronidazole, ornidazole, tinidazole), ketoconazole, procarbazine). It is necessary to avoid the simultaneous use of other drugs containing ethyl alcohol. If you are taking other medicines at the same time, you should consult your doctor. Doses and duration of administration are set by the doctor individually. Valocordin® is administered orally before meals 3 times a day, 15-20 drops, previously dissolved in a small amount of water. If sleep is disturbed, the dose can be increased to 30 drops. The drug is intended for episodic short-term use due to the risk of addiction and dependence. Contraindications – hypersensitivity to bromine or any component of the drug; – renal and / or liver failure; – porphyria; – alcoholism, epilepsy, traumatic brain injury and other brain diseases with a decrease in the seizure threshold; – pregnancy, lactation; – children’s age up to 18 years. Composition 1 ml (=20 drops) contains: Active ingredients: Phenobarbital – 18.4 mg Ethyl bromisovalerianate – 18.4 mg Excipients: mint oil, hop oil, ethanol 96%, purified water The drug contains 56% (v/v) alcohol ethyl. Overdose Symptoms of chronic overdose: depression of the central nervous system, nystagmus, ataxia, lowering blood pressure, blood count disorders, agitation, chronic bromine intoxication (depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, impaired coordination of movements). With the development of symptoms of an overdose, it is necessary to stop using the drug and consult a doctor. Acute overdose of barbiturates is manifested in the inhibition of the function of the central nervous system and the respiratory system: Cheyne-Stokes respiration, areflexia, oliguria, tachycardia, arterial hypotension, hypothermia and coma. Shock (apnea, circulatory collapse, respiratory arrest and death) may develop. With the development of symptoms of acute overdose, it is necessary to maintain the vital functions of the body and conduct detoxification therapy, resuscitation may be required. Side effect From the side of the nervous system: drowsiness, decreased concentration, slow reactions, impaired coordination of movements, dizziness, headache, nervousness, agitation, anxiety, confusion, increased motor activity, ataxia, depression of the central nervous system, sleep disturbances, insomnia, night nightmares, mental disorders, hallucinations. From the respiratory system: hypoventilation, apnea. On the part of the digestive system: nausea, vomiting, constipation, with prolonged use – impaired liver function. On the part of the hematopoietic organs: agranulocytosis, megaloblastic anemia, thrombocytopenia. From the cardiovascular system: bradycardia, low blood pressure, fainting. On the part of the musculoskeletal system: with prolonged use of drugs containing phenobarbital, there is a risk of impaired osteogenesis. There have been reports of reduced bone mineral density, the development of osteopenia and osteoporosis, fractures in patients who have been taking phenobarbital for a long time. Other: blurred vision, allergic reactions (angioedema, skin rash, ecofoliative dermatitis), fever, liver damage. With prolonged use – drug dependence. With prolonged use of large doses, chronic bromine poisoning may develop, the manifestations of which are: depressive mood, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, impaired coordination of movements. After prolonged use, megaloblastic anemia may develop. With the use of drugs containing phenobarbital, there have been reports of the development of life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis). In the event of adverse reactions, including those not listed in this leaflet, you should stop taking the drug and consult a doctor. Storage conditionsKeep in a place protected from light at a temperature not exceeding 25°C. Keep out of the reach of children. Buy Valocordin solution drops for oral administration 20ml No. 1 Price for Valocordin solution drops for oral administration 20 ml No. 1